Dl-Aminoglutethimide
Dl-Aminoglutethimide Brand names, Dl-Aminoglutethimide Analogs
Dl-Aminoglutethimide Brand Names Mixture
- No information avaliable
Dl-Aminoglutethimide Chemical_Formula
C13H16N2O2
Dl-Aminoglutethimide RX_link
http://www.rxlist.com/cgi/generic3/cytadren.htm
Dl-Aminoglutethimide fda sheet
Dl-Aminoglutethimide msds (material safety sheet)
Dl-Aminoglutethimide Synthesis Reference
Hoffmann, Urech, U.S. pat. 2,848,455 (1958 to Ciba)
Dl-Aminoglutethimide Molecular Weight
232.278 g/mol
Dl-Aminoglutethimide Melting Point
149-150 oC
Dl-Aminoglutethimide H2O Solubility
Practically insoluble in water
Dl-Aminoglutethimide State
Solid
Dl-Aminoglutethimide LogP
2.029
Dl-Aminoglutethimide Dosage Forms
Tablet (250 mg)
Dl-Aminoglutethimide Indication
For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.
Dl-Aminoglutethimide Pharmacology
Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens.
Dl-Aminoglutethimide Absorption
Rapidly and completely absorbed from gastrointestinal tract. The bioavailability of tablets is equivalent to equal doses given as a solution.
Dl-Aminoglutethimide side effects and Toxicity
Oral LD50s (mg/kg): rats, 1800; dogs, >100. Intravenous LD50s (mg/kg): rats, 156; dogs, >100. Symptoms of overdose include respiratory depression, hypoventilation, hypotension, hypovolemic shock due to dehydration, somnolence, lethargy, coma, ataxia, dizziness, fatigue, nausea, and vomiting.
Dl-Aminoglutethimide Patient Information
Dl-Aminoglutethimide Organisms Affected
Humans and other mammals
